Precipio (NASDAQ:PRPO) Announces Earnings Results

Precipio (NASDAQ:PRPO) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.81) earnings per share for the quarter, FiscalAI reports. The company had revenue of $6.71 million for the quarter. Precipio had a negative net margin of 1.51% and a negative return on equity of 2.78%.

Precipio Stock Performance

Precipio stock traded down $0.10 during mid-day trading on Thursday, reaching $28.60. 26,080 shares of the company’s stock were exchanged, compared to its average volume of 36,604. The business’s fifty day simple moving average is $27.86 and its 200 day simple moving average is $24.84. The company has a quick ratio of 1.36, a current ratio of 1.61 and a debt-to-equity ratio of 0.05. Precipio has a one year low of $7.05 and a one year high of $33.63. The firm has a market capitalization of $50.91 million, a PE ratio of -114.40 and a beta of 1.38.

Institutional Investors Weigh In On Precipio

Large investors have recently made changes to their positions in the business. Susquehanna International Group LLP purchased a new position in shares of Precipio in the 3rd quarter worth about $194,000. Renaissance Technologies LLC grew its position in Precipio by 10.7% during the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 1,400 shares during the period. Evernest Financial Advisors LLC purchased a new stake in Precipio during the third quarter worth about $374,000. Geode Capital Management LLC raised its position in Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 789 shares during the period. Finally, Topline Capital Management LLC bought a new stake in Precipio in the third quarter worth about $1,158,000. 10.45% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on PRPO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a report on Tuesday, April 21st. Wall Street Zen upgraded shares of Precipio from a “hold” rating to a “buy” rating in a report on Saturday, April 4th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.